Every earnings call for PPLPHARMA — management tone, guidance, KPIs and promise tracking, quarter by quarter.
PPLPHARMA · 6 transcripts · Healthcare · latest Q4 FY26Intangible Write-down ₹176 cr; Net Debt-to-EBITDA 3.6 x; Net Promoter Score 60 score. CDMO business reported revenues of INR 4,915 crores for the full year FY26.
Read full transcript & analysisRevenue ₹2,140 cr (−4% YoY); EBITDA Margin 11%; Net Debt ₹4,200 cr. Revenue for Q3 FY26 reported at ₹2,140 crores, representing a Y-o-Y decline of approximately 3-4%.
Read full transcript & analysisConsolidated PAT ₹327 cr (+101% YoY). Consolidated Profit After Tax (PAT) reached ₹327 crores, a 101% YoY increase.
Read full transcript & analysisRevenue 1000 USD millions (+12% YoY); EBITDA Margin 17%; PAT ₹91 cr (+405% YoY). Surpassed USD 1 billion annual revenue milestone in FY25 with 12% YoY growth.
Read full transcript & analysis9M Revenue Growth 0.14% (+14% YoY); 9M EBITDA Growth 0.2% (+20% YoY); Net Debt to EBITDA 2.8 x. 9M FY25 revenue grew 14% YoY, with EBITDA growing approximately 20% during the same period.
Read full transcript & analysisEBITDA Margin 18%. Consolidated revenue grew 17% YoY in Q2 FY25, driven by strong performance across all business verticals.
Read full transcript & analysis